Scarica l'app Stockscreener
2.60
0.98%
-0.0256
Dopo l'orario di chiusura:
2.60
Precedente Chiudi:
$2.6256
Aprire:
$2.6
Volume 24 ore:
29,099
Relative Volume:
0.97
Capitalizzazione di mercato:
$7.88M
Reddito:
-
Utile/perdita netta:
$2.81M
Rapporto P/E:
-0.1812
EPS:
-14.3497
Flusso di cassa netto:
$7.14M
1 W Prestazione:
-13.62%
1M Prestazione:
-20.00%
6M Prestazione:
-21.45%
1 anno Prestazione:
-51.69%
Intervallo 1D:
$2.51
$2.9199
Intervallo di 1 settimana:
$2.51
$3.0299
Portata 52W:
$2.51
$5.76
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Nome
Kiora Pharmaceuticals Inc
Settore
Industria
Telefono
781-788-8869
Indirizzo
332 ENCINITAS BOULEVARD, ENCINITAS
Confronta KPRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.60 | 7.88M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Kiora Pharmaceuticals Inc Borsa (KPRX) Ultime notizie
Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference - Newsfile
Kiora Unveils Latest Progress on Two Phase 2 Retinal Disease Treatments - Stock Titan
Kiora Pharmaceuticals (NASDAQ:KPRX) Earns “Buy” Rating from HC Wainwright - Defense World
Kiora Pharmaceuticals Advances Retinal Disease Pipeline - TipRanks
Kiora Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027 - TradingView
Kiora Achieves Breakthrough Year: $3.6M Profit as Retinal Disease Pipeline Expands - Stock Titan
CNS Pharma Stock Price, Quotes and Forecasts | NASDAQ:CNSP - Benzinga
Kiora Pharmaceuticals Inc expected to post a loss of 55 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals (KPRX) Expected to Announce Quarterly Earnings on Monday - Defense World
Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting - Newsfile
Breakthrough Eye Treatment: Kiora's KIO-104 Could Prevent Post-Surgery Scarring - StockTitan
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Up 281.5% in February - Defense World
Kiora Pharmaceuticals secures new patent for KIO-104 - MSN
Addex Therapeutics (OTCMKTS:ADDXF) vs. Kiora Pharmaceuticals (NASDAQ:KPRX) Head-To-Head Contrast - Defense World
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Significant Growth in Short Interest - Defense World
Kiora Pharmaceuticals secures new patent for KIO-104 By Investing.com - Investing.com Nigeria
Patent Victory: Kiora's Eye Drug Gets 20-Year Protection, Phase 2 Trial Coming in 2025 - StockTitan
Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104 - Newsfile
Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema - Newsfile
Retinitis Pigmentosa Treatment Market Industry Growth - openPR
US Exchange Penny Stocks To Watch In January 2025 - Simply Wall St
Promising US Penny Stocks To Consider In January 2025 - Simply Wall St
3 US Penny Stocks With Market Cap Under $70M - Yahoo Finance
January 2025's Top US Penny Stocks To Consider - Yahoo Finance
Kiora Pharmaceuticals, Inc. Announces Promotion of Melissa Tosca to Chief Financial Officer - Marketscreener.com
Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Down 5.9% – Here’s What Happened - Defense World
3 US Penny Stocks With Market Caps Under $200M - Simply Wall St
US Penny Stocks: 3 Picks With Market Caps Below $400M - Yahoo Finance
3 US Penny Stocks With Market Caps Under $100M To Watch - Yahoo Finance
Cerus And 2 Other US Penny Stocks With Promising Potential - Yahoo Finance
3 Promising US Penny Stocks With Over $9M Market Cap - Simply Wall St
US Penny Stocks To Watch In January 2025 - Yahoo Finance
3 Promising US Penny Stocks With Market Caps Under $80M - simplywall.st
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 0.6% Higher – Should You Buy? - Defense World
Retinitis Pigmentosa Treatment Market Report: Detailed - openPR
Persistent Epithelial Defect Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Kiora Pharma, Combangio, Inc, Santen Pharmaceutical, Amber Ophthalmics, Noveome - The Globe and Mail
Persistent Epithelial Defect Market Statistics Expected - openPR
Uveitis Market Forecasted for Major Expansion by 2031 | Novartis - openPR
Eyegate Pharmaceuticals Receives Canadian Patent for Proprietary Iontophoretic Formulation and Use - Marketscreener.com
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire Inc.
Advancing Stargardt Disease Treatments: 20+ Companies Poised to Accelerate the Therapeutic Pipeline | DelveInsight - GlobeNewswire
What is HC Wainwright’s Estimate for KPRX FY2024 Earnings? - Defense World
ADAR1 Capital Management, LLC Increases Stake in Kiora Pharmaceu - GuruFocus.com
Alyeska Investment Group L.P. Expands Portfolio with Kiora Pharm - GuruFocus.com
We Think Kiora Pharmaceuticals' (NASDAQ:KPRX) Healthy Earnings Might Be Conservative - Yahoo Finance
Goldman Sachs Acquires New Stake in Kiora Pharmaceuticals - GuruFocus.com
Kiora Pharmaceuticals retains stock target and Buy rating on loss report - Investing.com UK
Kiora Pharmaceuticals (KPHMW) Quarterly 10-Q Report - Quartzy
Kiora Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies - Newsfile
Kiora Pharmaceuticals Inc Azioni (KPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):